Attorney Advertising
Are you a Zenas BioPharma, Inc. (NASDAQ: ZBIO) investor who bought shares in the company’s September 2024 IPO? If so, you may be eligible to join a class action lawsuit now pending in the U.S. District Court for Massachusetts.
The lawsuit alleges that the IPO Registration Statement included materially false and misleading statements and omitted critical information. In particular, it is alleged to have overstated the duration for which Zenas could fund operations with IPO proceeds and existing cash. Read more about the case.
To learn about your legal options, please complete the form below. You may also contact partner Molly J. Bowen at (202) 408-4600 or mbowen@cohenmilstein.com.
CASE BACKGROUND: Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology-based therapies. A complaint filed on April 16, 2025, in the U.S. District Court for the District of Massachusetts alleges that the company, certain executives and directors, and the underwriters of its IPO violated federal securities laws. The complaint alleges that the Registration Statement for the IPO contained materially false and misleading statements and omitted critical information, particularly overstating the duration Zenas could fund operations with IPO proceeds and existing cash.
Shortly after the IPO, Zenas BioPharma revealed in its third quarter 2024 financial results that it could fund operations for 12 months—not 24 months as previously stated. Following this disclosure, Zenas shares fell significantly, closing at $8.72 per share on April 15, 2025, nearly 49% below the IPO price of $17.00 per share.
NEXT STEPS: If you purchased shares of Zenas BioPharma pursuant and/or traceable to the September 2024 IPO and suffered a significant loss, and are interested in serving as lead plaintiff, you must move the court no later than June 16, 2025, to request appointment as lead plaintiff. You are not required to file a lead plaintiff motion to participate in any potential recovery as a class member.
OUR FIRM: With more than 100 attorneys in eight offices, Cohen Milstein is one of the largest plaintiff-side law firms in the U.S., with over four decades of experience litigating securities fraud cases. We have recovered billions of dollars for investors and are consistently recognized by The National Law Journal, Law360, Chambers USA, and The Legal 500 as a top securities litigation practice. For more information, visit www.cohenmilstein.com.
Prior results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION:
Molly Bowen, Esq.
Cohen Milstein Sellers & Toll PLLC
Washington, D.C. Office
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com